Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | NQO2 | P16083 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1901172 | 0.91 | ALDH1A1 (0.76) | HSD17B10ALDH1A1CYP1A2NAPRTRAB9A | |
| SCHEMBL11858223 | 0.89 | GPR35 (0.67) | HSD17B10POLBKMT2AMEN1TP53 | |
| SCHEMBL19501805 | 0.84 | KMT2A (0.81) | HSD17B10ALDH1A1CYP1A2NAPRTRAB9A | |
| SCHEMBL30557361 | 0.84 | KMT2A (0.81) | HSD17B10ALDH1A1CYP1A2NAPRTRAB9A | |
| SCHEMBL31436022 | 0.84 | MAPT (0.75) | HSD17B10ALDH1A1CYP1A2NAPRTRAB9A | |
| SCHEMBL1934668 | 0.84 | MAPT (0.75) | HSD17B10ALDH1A1CYP1A2NAPRTRAB9A | |
| SCHEMBL12133 | 0.83 | HSD17B10 (1.00) | HSD17B10ALDH1A1CYP1A2NAPRTRAB9A | |
| SCHEMBL697192 | 0.83 | GPR35 (0.55) | HSD17B10ALDH1A1CYP1A2RAB9APOLB | |
| SCHEMBL1487964 | 0.83 | ALDH1A1 (0.66) | HSD17B10ALDH1A1CYP1A2NAPRTRAB9A | |
| SCHEMBL30703669 | 0.83 | HSD17B10 (1.00) | HSD17B10ALDH1A1CYP1A2NAPRTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017153952-A1 | 5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017098421-A1 | BENZOTHIADIAZINE COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| EP-1737463-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080249075-A1 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| EP-1737462-B1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
| US-20080027076-A1 | Pyrimidines With Tie2 (Tek) Activity | ASTRAZENECA AB (SE) | 2008-01-31 | — | — | US | disclosed |
| CN-1917880-A | Pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| CN-1917879-A | Pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| EP-1737462-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | AstraZeneca AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005060969-A1 | PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108608-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | HSD17B10 4695/4885ALDH1A1 1339/4885CYP1A2 2490/4885 |
| US-20080249075-A1 | C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds | HSD17B11, CYP19A1, ESRRA | HSD17B10 115/4885ALDH1A1 1234/4885CYP1A2 222/4885 |
| US-20080027076-A1 | Pyrimidines With Tie2 (Tek) Activity | TIE1, TEK, TEKT1 | HSD17B10 4719/4885ALDH1A1 1331/4885CYP1A2 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.